Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
donepezil · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| sugar pill | PLACEBO_COMPARATOR | - |
| donepezil | ACTIVE_COMPARATOR | - |
| ABT-126 Low Dose | EXPERIMENTAL | low dose |
| ABT-126 Middle Dose | EXPERIMENTAL | middle dose |
| ABT-126 high dose | EXPERIMENTAL | high dose |
| Name | Type | Description |
|---|---|---|
| placebo | DRUG | Placebo Comparator |
| donepezil | DRUG | Active Comparator |
| ABT-126 | DRUG | low dose, middle dose, high dose |
Inclusion Criteria: * The subject and caregiver must voluntarily sign and date an informed consent. If the subject does not have the capacity to provide informed consent, full informed consent must be obtained from the subject's representative and assent must be obtained from the subject. * The sub...
Top 20 of 24 competitors
Donepezil is an investigational small molecule being studied for the treatment of Alzheimer's Disease. It is currently in Phase 2 clinical development, having completed a trial in patients with mild to moderate Alzheimer's Disease. The drug is being developed by AbbVie Inc. and is not yet approved for this use.
The specific molecular target of donepezil is not disclosed in the available information. The drug is a small molecule being evaluated for its efficacy and safety in patients with mild to moderate Alzheimer's Disease. Its mechanism of action has not been publicly detailed in the context of this development program.
Donepezil is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The company is conducting clinical trials to evaluate the drug's potential in treating Alzheimer's Disease, with the most recent study having been completed.
Donepezil is in Phase 2 clinical development for Alzheimer's Disease. A Phase 2 trial has been completed, involving 438 participants with mild to moderate Alzheimer's Disease. The drug remains investigational and has not received regulatory approval for any indication.
Donepezil has been studied in one completed Phase 2 clinical trial, identified as NCT01527916. This randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of the drug in 438 subjects with mild to moderate Alzheimer's Disease across multiple countries, including the United States, Poland, Russia, South Africa, Ukraine, and the United Kingdom.
Yes, donepezil is the same as ABT-126. The Phase 2 clinical trial NCT01527916, which evaluated the drug in subjects with mild to moderate Alzheimer's Disease, was titled 'Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease.' This confirms that ABT-126 is the investigational name for donepezil.